Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 22, Issue 6, 2006, Pages 336-342

  Yilmaz, Murat ^a   Ali Ergün, Mehmet ^b   Karakoç, Ayhan ^b   Yurtçu, Erkan ^b   Çakir, Nuri ^b   Arslan, Metin ^b  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Androgens; Insulin resistance; Obesity; Peroxisome proliferator activated receptor gene; Polycystic ovary syndrome; Pro12Ala polymorphism

Indexed keywords

ALANINE; ANDROSTENEDIONE; C PEPTIDE; FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRASTERONE SULFATE; PROLINE; SEX HORMONE; TESTOSTERONE;

ACNE; ADULT; ALLELE; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FERRIMAN GALLWEY SCORE; GENETIC POLYMORPHISM; HETEROZYGOTE; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; WAIST HIP RATIO;

ADULT; ALANINE; ANDROSTENEDIONE; BLOOD GLUCOSE; C-PEPTIDE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; FOLLICLE STIMULATING HORMONE; GLUCOSE TOLERANCE TEST; HETEROZYGOTE; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PPAR GAMMA; PROLINE; TESTOSTERONE;

EID: 33745366449     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590600733357     Document Type: Article

References (35)

1. Frank S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
2. Homburg R. What is polycystic ovarian syndrome? Hum Reprod 2003;17:2495-2499.
3. Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
5. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
6. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association. Endocr Rev 2003;24:302-312.
7. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600.
8. Franks S, Gharani N, McCarthy M. Candidate genes in polycystic ovary syndrome. Hum Reprod Update 2001;7:405-410.
9. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, Berger J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun 1996;22:431-437.
10. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci 2004;25:331-336.
11. Deeb SS, Fajas L, Nemoto M, Pihlamajaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx JA. A Pro12Ala substitution in PPAR γ2 is associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1988;20:284-287.
12. Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M, Loblein K, Maerker E, Volk A, Renn W, Balletshofer B. PPAR-γ2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 2000;32:413-416.
13. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
14. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, et al. The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000;271:212-216.
15. Lei H, Chen M, Yang W, Chiu M, Chen M, Tai T, Chuang L. Peroxisome proliferator-activated receptor γ2 Pro12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism 2000;49:1267-1270.
16. Cole S, Mitchell B, Hsueh W-C, Pineda P, Beamer B, Shuldiner A, Comuzzie A, Blangero J, Hixson J. The Pro12Ala variant of peroxisome proliferator- activated receptor-γ2 (PPAR-γ2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord 2000;24:522-524.
17. Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb S, Auwerx J, Uusitupa M, Laakso M. Two polymorphisms in the peroxisome proliferator-activated receptor-γ gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999;84:3708-3712.
18. Beamer B, Yen CJ, Andersen R, Muller D, Elahi D, Cheslin L. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ gene with obesity in two Caucasian population. Diabetes 1998:47:1806-1808.
19. Mancini F, Vaccaro O, Sabatino L, Tufano A, Rivellese A, Riccardi G, Colantuoni V. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ2 is not associated with type 2 diabetes. Diabetes 1999;48:1466-1468.
20. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrman DA. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro12Ala polymorphism in the PPAR γ gene. J Clin Endocrinol Metab 2002;87:772-775.
21. Tok EC, Aktas A, Ertunc D, Erdal EM, Dilek S. Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-γ2 Pro12Ala genotype. Hum Reprod 2005;20:1590-1595.
22. Hahn S, Fingerhut A, Khomtsiv U, Khomtsiv L, Tan S, Quadbeck S, Herrmann BL, Knebel B, Müller-Wieland D, Mann K, et al. The peroxisome proliferator activated receptor γ Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005;62:573-579.
23. San Millian JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004;89:2640-2646.
24. Korhonen S, Heinonen S, Hiltunen M, Helisalmi S, Hippelainen M, Koivunen R, Tapanaien JS, Laakso M. Polymorphisms in the peroxisome proliferator- activated receptor-γ gene in women with polycystic ovary syndrome. Hum Reprod 2003;18:540-543.
25. Orio F Jr, Matarese G, Di Biase S, Palomba S, Labella D, Sana V, Savastano S, Zullo F, Colao A, Lombardi G. Exon 6 and 2 peroxisome proliferator-activated receptor-γ polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:887-892.
26. Orio F Jr, Palomba S, Cascella T, Di Biase S, Labella D, Russo T, Savastano S, Zullo F, Colao A, Vettor R, et al. Lack of an association between peroxisome proliferator-activated receptor-γ gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5110-5115.
27. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
28. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
29. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
31. American Diabetes Association. Screening for diabetes. Diabetes Care 2002;25:21-24.
32. Pihlajamaki J, Miettinen R, Valve R, Karjalainen L, Mykkanen L, Kuusisto J, Deeb S, Auwerx J, Laakso M. Pro12Ala substitution in the peroxisome proliferator-activated γ2 is associated with famialial combined hyperlipidemia and non-diabetic elderly subjects with dyslipidemia. Atherosclerosis 2000;151:567-574.
33. Ringel J, Engeli S, Distler A, Sharma AM. Pro12Ala missense mutation of the peroxisome proliferator-activated receptor-γ and diabetes mellitus. Biochem Biophys Res Commun 1999;254:450-453.
34. Hamann A, Munzberg H, Buttron P, Pusing B, Hinney A, Mayer H, Siegfried W, Hebebrand J, Greten H. Missense variants in the human peroxisome proliferator-activated receptor-γ2 gene in lean and obese subjects. Eur J Endocrinol 1999;141:90-92.
35. Mori Y, Kim-Motoyama H, Katakura T, Yasuda K, Kadowaki H, Beamer BA, Shldiner AR, Akanuma Y, Yazaki Y, Kadowaki T. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor-γ2 gene on adiposity, fat distrubution, and insulin sensivity in Japanese men. Biochem Biophys Res Commun 1998;251:195-198.